Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Technical feasibility of personalized articulating knee joint distraction for treatment of tibiofemoral osteoarthritis.

Struik T, Jaspers JEN, Besselink NJ, van Roermund PM, Plomp S, Rudert MJ, Lafeber FPJG, Mastbergen SC.

Clin Biomech (Bristol, Avon). 2017 Aug 12;49:40-47. doi: 10.1016/j.clinbiomech.2017.08.002. [Epub ahead of print]

PMID:
28865300
2.

Mind-body medicine and lifestyle modification in supportive cancer care: A cohort study on a day care clinic program for cancer patients.

Jeitler M, Jaspers J, von Scheidt C, Koch B, Michalsen A, Steckhan N, Kessler CS.

Psychooncology. 2017 Mar 31. doi: 10.1002/pon.4433. [Epub ahead of print]

PMID:
28370730
3.

Development of CAR T cells designed to improve antitumor efficacy and safety.

Jaspers JE, Brentjens RJ.

Pharmacol Ther. 2017 Oct;178:83-91. doi: 10.1016/j.pharmthera.2017.03.012. Epub 2017 Mar 22. Review.

PMID:
28342824
4.

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.

Warmoes M, Lam SW, van der Groep P, Jaspers JE, Smolders YH, de Boer L, Pham TV, Piersma SR, Rottenberg S, Boven E, Jonkers J, van Diest PJ, Jimenez CR.

Oncotarget. 2016 Sep 27;7(39):63537-63548. doi: 10.18632/oncotarget.11535.

5.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.

Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.

PMID:
27550455
6.

Epidemiology of RBC Transfusions in Patients With Severe Acute Kidney Injury: Analysis From the Randomized Evaluation of Normal Versus Augmented Level Study.

Bellomo R, Mårtensson J, Kaukonen KM, Lo S, Gallagher M, Cass A, Myburgh J, Finfer S; Randomized Evaluation of Normal Versus Augmented Level of Replacement Therapy Study Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group.

Crit Care Med. 2016 May;44(5):892-900. doi: 10.1097/CCM.0000000000001518.

PMID:
26619086
7.

Prognostic Factors for Distress After Genetic Testing for Hereditary Cancer.

Voorwinden JS, Jaspers JP.

J Genet Couns. 2016 Jun;25(3):495-503. doi: 10.1007/s10897-015-9894-9. Epub 2015 Oct 16.

8.

Phenotypic Suppression of Streptomycin Resistance by Mutations in Multiple Components of the Translation Apparatus.

Carr JF, Lee HJ, Jaspers JB, Dahlberg AE, Jogl G, Gregory ST.

J Bacteriol. 2015 Sep;197(18):2981-8. doi: 10.1128/JB.00219-15. Epub 2015 Jul 6.

9.

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP, de Korte-Grimmerink R, Gogola E, Szuhai K, Schlicker A, Bin Ali R, Pritchard C, Huijbers IJ, Berns A, Rottenberg S, Jonkers J.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8409-14. doi: 10.1073/pnas.1500223112. Epub 2015 Jun 22.

10.

A novel, intuitive instrument positioner for endoscopy, involving surgeons in design and feasibility.

Bosma J, Boeken Kruger A, Jaspers J.

Minim Invasive Ther Allied Technol. 2015;24(6):326-33. doi: 10.3109/13645706.2015.1039547. Epub 2015 Apr 28.

PMID:
25921385
11.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S.

Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.

12.

The Minimally Invasive Manipulator: an ergonomic and economic non-robotic alternative for endoscopy?

Bosma J, Aarts S, Jaspers J.

Minim Invasive Ther Allied Technol. 2015 Feb;24(1):24-30. doi: 10.3109/13645706.2014.992906.

PMID:
25627434
13.

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J, Rottenberg S.

Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15.

14.

Monitoring of tumor response to Cisplatin using optical spectroscopy.

Spliethoff JW, Evers DJ, Jaspers JE, Hendriks BH, Rottenberg S, Ruers TJ.

Transl Oncol. 2014 Apr;7(2):230-9. doi: 10.1016/j.tranon.2014.02.009. Epub 2014 Mar 4.

15.

Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing.

van Driel CM, Eltahir Y, de Vries J, Jaspers JP, Oosterwijk JC, Mourits MJ, de Bock GH.

Maturitas. 2014 Feb;77(2):180-4. doi: 10.1016/j.maturitas.2013.10.017. Epub 2013 Nov 1.

PMID:
24268650
16.

Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus.

Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT, Doevendans PA, Verhaar MC.

PLoS One. 2013;8(3):e60357. doi: 10.1371/journal.pone.0060357. Epub 2013 Mar 28.

17.

Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.

Warmoes M, Jaspers JE, Xu G, Sampadi BK, Pham TV, Knol JC, Piersma SR, Boven E, Jonkers J, Rottenberg S, Jimenez CR.

Mol Cell Proteomics. 2013 May;12(5):1319-34. doi: 10.1074/mcp.M112.024182. Epub 2013 Feb 8.

18.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

19.

The use of near-infrared light for safe and effective visualization of subsurface blood vessels to facilitate blood withdrawal in children.

Cuper NJ, Klaessens JH, Jaspers JE, de Roode R, Noordmans HJ, de Graaff JC, Verdaasdonk RM.

Med Eng Phys. 2013 Apr;35(4):433-40. doi: 10.1016/j.medengphy.2012.06.007. Epub 2012 Jul 27.

PMID:
22841651
20.

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.

Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6.

Supplemental Content

Loading ...
Support Center